HC Wainwright & Co. Downgrades Harpoon Therapeutics to Neutral, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Harpoon Therapeutics (NASDAQ:HARP) from Buy to Neutral, while increasing the price target from $12 to $23.
January 08, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Harpoon Therapeutics was downgraded from Buy to Neutral by HC Wainwright & Co., although the price target was raised from $12 to $23.
The downgrade to Neutral suggests that the analyst sees limited upside potential or increased risk in the stock, which could lead to short-term price stagnation. However, the significant increase in the price target from $12 to $23 indicates a positive long-term outlook, which might balance out the short-term impact. Investors may react cautiously due to the mixed signals, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100